Poncirus Trifoliata (L.) Raf. Extract Inhibits the Development of Atopic Dermatitis-like Lesions in Human Keratinocytes and NC/Nga mice.
This study investigated the anti-allergic effect of Poncirus trifoliata (L.) Raf. (PT) on human keratinocytic HaCaT cells in vitro and on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis-like lesions in vivo. The release of TARC, MCP-1, IL-6 and IL-8 is increased by IFN-γ and TNF-α in HaCaT cells, and PT extract suppressed the increased production of TARC, MCP-1, IL-6, and IL-8. PT extract recovered the expression of filaggrin decreased by IFN-γ and TNF-α. in vivo experiment, PT administration decreased the skin severity score, thickening of the epidermis, movement of inflammatory cells into the dermis, and serum IgE level as compared to DNCB treatment. Moreover, the decrease of filaggrin and loricrin induced by DNCB treatment was recovered by PT administration. The levels of IL-4, IL-5, IL-13 and eotaxin in mouse splenocytes increased after treatment with concanavalin A, and the secretions of IL-4, IL-5, IL-13 and eotaxin were lower in the PT-treated group than in the DNCB group. These findings may indicate that PT is useful in drug development for the treatment of AD. PMID: 31523174 [PubMed - in process]
Authors: Maloney NJ, Tegtmeyer K, Zhao J, Worswick S Abstract Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different dermatologic conditions, including allergic c...
Authors: Sheriff T, Lin MJ, Dubin D, Khorasani H Abstract Cannabis is increasingly being used world-wide to treat a variety of dermatological conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 countries in Europe. The authors reviewed the literature on the pharmacology and use of cannabinoids in treating a variety of skin conditions including acne, atopic dermatitis, psoriasis, skin cancer, pruritus, and pain. Cannabinoids have demonstrated anti-inflammatory, antipruritic, anti-ageing, and antimalignancy properties by various mechanisms including interacting with the newly ...
ConclusionsThe present study allowed the identification of different protein areas specific to these studied groups. The protein spots of interest were identified by UHPLC-MS/MS. It has been possible to establish a link between a specific symptomatology and the newly identified responsible allergens.
Chandra Sekhar Sirka, Kananbala Sahu, Swetalina Pradhan, Arpita Nibedita RoutIndian Journal of Dermatology, Venereology, and Leprology 2019 85(6):623-626
Conclusions. Hypozincemia is rather prevalent in AD, and severe AD and high IgE increase its risk. An adjunct oral zinc may help reducing severe poorly responsive AD. PMID: 31594297 [PubMed - as supplied by publisher]
Treatment for children with moderate-severe atopic dermatitis is a significant unmet need; dupilumab is currently licensed only for patients over age 11.Off-label access to dupilumab is achievable, and shows similar treatment success rates and tolerability as in adult patients, but optimal pediatric dosing has not been defined..
Applying strips of tape to collect skin samples for biomarker testing may be a viable alternative to biopsy for serial evaluation of early-onset atopic dermatitis in children.Medscape Medical News
This cross-sectional study examines whether tape strips might be used to detect immune and barrier abnormalities and to define biomarkers associated with atopic dermatitis in children younger than 5 years with early-onset atopic dermatitis.
Atopic dermatitis (AD) is predominantly a disease of infancy and childhood, yet there are few studies investigating the immune profile of the skin in this population. Thus, relevant AD biomarkers are largely lacking, especially for stratification of the disease ’s severity, progression, and response to therapy. This gap is especially relevant as new medications for AD become available for the pediatric group, necessitating decision-making about which children will benefit. Some of the limitations for such data collection are related to the difficulty wit h obtaining samples in a research setting from infants and chil...
We report that a recently treated patient with the full spectrum of 3D clinical features of pellagra presents as chronic diarrhea of unknown etiology for 1 year. It reminds us that keeping a high index of suspicion and maintaining a broad differential diagnosis are critical for recognition and management of this potentially fatal but treatable condition. PMID: 31599018 [PubMed - as supplied by publisher]